08:07 AM EDT, 07/30/2025 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) reported Q2 non-GAAP earnings Wednesday of $0.66 per diluted share, up from $0.61 a year earlier.

Analysts surveyed by FactSet expected $0.62.

Revenue for the quarter ended June 30 was $4.18 billion, up from $4.16 billion a year earlier.

Analysts surveyed by FactSet expected $4.27 billion.

The company said it now expects 2025 adjusted EPS of $2.50 to $2.65, compared with $2.45 to $2.65 previously. Analysts polled by FactSet expect $2.53.

Revenue for the current year is still expected to be $16.8 billion to $17.2 billion, the company said. Analysts surveyed by FactSet expect $16.89 billion.